The race to develop and commercialize effective weight loss drugs has been heating up in 2024. Eli Lilly's (LLY) Mounjaro and Novo Nordisk's (NVO) Wegovy, part of the new GLP-1 drug class, have been making major waves by helping people shed up to 20% of their body weight, on average.
With obesity among U.S. adults trending steadily higher, it's no surprise that analysts think the weight-loss drug market could balloon to $50 billion in annual sales by 2030. That's a massive opportunity.
